Statutory Instrument 1999 No. 2535

      The Medicines (Products Other Than Veterinary Drugs) (General Sale List) Amendment (No. 2) Order 1999


      © Crown Copyright 1999

      Statutory Instruments printed from this website are printed under the superintendence and authority of the Controller of HMSO being the Queen's Printer of Acts of Parliament.

      The legislation contained on this web site is subject to Crown Copyright protection. It may be reproduced free of charge provided that it is reproduced accurately and that the source and copyright status of the material is made evident to users.

      It should be noted that the right to reproduce the text of Statutory Instruments does not extend to the Queen's Printer imprints which should be removed from any copies of the Statutory Instrument which are issued or made available to the public. This includes reproduction of the Statutory Instrument on the Internet and on intranet sites. The Royal Arms may be reproduced only where they are an integral part of the original document.

      The text of this Internet version of the Statutory Instrument which is published by the Queen's Printer of Acts of Parliament has been prepared to reflect the text as it was Made. A print version is also available and is published by The Stationery Office Limited as the The Medicines (Products Other Than Veterinary Drugs) (General Sale List) Amendment (No. 2) Order 1999 , ISBN 0 11 085237 0. The print version may be purchased by clicking here. Braille copies of this Statutory Instrument can also be purchased at the same price as the print edition by contacting TSO Customer Services on 0870 600 5522 or e-mail:customer.services@tso.co.uk.

      Further information about the publication of legislation on this website can be found by referring to the Frequently Asked Questions.

      To ensure fast access over slow connections, large documents have been segmented into "chunks". Where you see a "continue" button at the bottom of the page of text, this indicates that there is another chunk of text available.


STATUTORY INSTRUMENTS


1999 No. 2535

MEDICINES

The Medicines (Products Other Than Veterinary Drugs) (General Sale List) Amendment (No. 2) Order 1999

  Made 8th September 1999 
  Coming into force 30th September 1999 

The Secretaries of State concerned with health in England, in Wales and in Scotland respectively and the Department of Health and Social Services for Northern Ireland, acting jointly, in exercise of the powers conferred on them by sections 51 and 129(4) of the Medicines Act 1968[1] or, as the case may be, those conferred by those provisions and now vested in them[2], and of all other powers enabling them in that behalf, after consulting such organisations as appear to them to be representative of interests likely to be substantially affected by this Order pursuant to section 129(6) of that Act and after taking into account the advice of the Medicines Commission pursuant to section 129(7) of that Act, hereby make the following Order:

Citation, commencement and interpretation
     1.  - (1) This Order may be cited as the Medicines (Products Other Than Veterinary Drugs) (General Sale List) Amendment (No. 2) Order 1999 and shall come into force on 30th September 1999.

    (2) In this Order - 

Amendment of Schedule 1 to the principal Order
     2.  - (1) Table A of Schedule 1 is amended as follows - 

    (a) against the entry for "Ibuprofen"[4], there is inserted in column 3, in the entry numbered "(2)", before the words "rheumatic pain", the word "backache";

    (b) against the entry for "Lignocaine Hydrochloride"[5], there is inserted - 

      (i) in column 2, after the entry numbered "(2)", the words "(3) 2.0 per cent"; and

      (ii) in column 3, after the entry numbered "(2)", the words "(3) External, except local ophthalmic use; for use in adults and in children aged 12 years and over; all preparations except sprays"; and

    (c) against the entry for "Zinc Sulphate", there is substituted for the entry in column 2 "(2) 0.25 per cent", the entry "(2) 1.0 per cent".

    (2) In Table A of Schedule 1, there is inserted in column 1, at the appropriate place in the alphabetical order of the entries as they appear in that column, the entry set out in column 1 below, and, against that entry, there is inserted in columns 2, 3 and 4 the corresponding text in columns 2, 3 and 4 below:

Column 1 Column 2 Column 3 Column 4
Substance Maximum strength Use, pharmaceutical form or route of administration Maximum dose and maximum daily dose
Ranitidine Hydrochloride 75mg Tablets; for the short term symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity 150mg (MDD).



Signed by authority of the Secretary of State for Health


Hunt
Parliamentary Under Secretary of State, Department of Health

6th September 1999


David Hanson
Parliamentary Under Secretary of State, The Welsh Office

8th September 1999


John Reid
Secretary of State, The Scotland Office

8th September 1999



Sealed with the Official Seal of the Department of Health and Social Services for Northern Ireland on

L.S.


D. C. Gowdy
Permanent Secretary

8th September 1999



EXPLANATORY NOTE

(This note is not part of the Order)


This Order further amends the Medicines (Products Other Than Veterinary Drugs) (General Sale List) Order 1984 ("the principal Order") which specifies classes of medicinal products which can with reasonable safety be sold or supplied otherwise than by or under the supervision of a pharmacist (the general sale list).

Article 2 amends Schedule 1 to the principal Order (medicinal products, other than products the subject of a product licence of right, on general sale) by amending Table A (internal or external use) - 

    (a) in respect of the entry for Ibuprofen, by inserting a reference to external use for the treatment of backache;

    (b) in respect of the entry for Lignocaine Hydrochloride, by inserting a reference to products of maximum strength 2.0 per cent, for external use except local ophthalmic use, for use in adults and in children aged 12 years and over, and in any type of preparation except sprays;

    (c) in respect of the entry for Zinc Sulphate, to increase the maximum strength, for external use, from 0.25 per cent to 1.0 per cent; and

    (d) in respect of Ranitidine Hydrochloride, to insert an entry for products of maximum strength 75 mg, for the short term symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity with a maximum daily dose of 150 mg.

An assessment of the cost to business of complying with this Order has been made, copies of which have been placed in the libraries of both Houses of Parliament. Further copies may be obtained from the Department of Health, Medicines Control Agency, Information Centre, Room 1207, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.


Notes:

[1] 1968 c. 67; section 1(1)(a) of the 1968 Act, as amended by S.I. 1969/388, contains a definition of "the Health Ministers" and section 1(2) contains a definition of "the appropriate Ministers", both of which are relevant to the powers being exercised in the making of this Order.back

[2] In the case of the Secretaries of State concerned with health in England and in Wales, by virtue of article 2(2) of, and Schedule 1 to, S.I. 1969/388; in the case of the Department of Health and Social Services for Northern Ireland, by virtue of section 40 of, and Schedule 5 to, the Northern Ireland Constitution Act 1973 (c. 36) and section 1(3) of, and paragraph 2(1)(b) of Schedule 1 to, the Northern Ireland Act 1974 (c. 28).back

[3] S.I. 1984/769, amended by S.I. 1985/1540, 1987/910, 1989/969, 1990/1129, 1992/1535, 1994/2410, 1995/3216, 1997/2043, 1998/2170 and 1999/852.back

[4] Entry inserted by S.I. 1995/3216.back

[5] Entry inserted by S.I. 1994/2410.back



ISBN 0 11 085237 0


 

Other UK SIs | Home | National Assembly for Wales Statutory Instruments | Scottish Statutory Instruments | Statutory Rules of Northern Ireland |  Her Majesty's Stationery Office


We welcome your comments on this site
© Crown copyright 1999
Prepared 16 September 1999